Filter
435
Text search:
mHGAP
Featured
99
69
Language
Document type
244
68
40
39
14
12
7
7
2
1
1
Countries / Regions
14
14
14
14
14
12
11
9
7
6
5
5
5
5
4
4
4
4
4
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
94
25
17
15
10
7
2
Toolboxes
265
41
25
12
9
9
8
6
6
6
5
3
3
2
2
2
2
Addressing comorbidities and risk factors for tuberculosis (TB) is a crucial component of the World Health Organization (WHO)’s End TB Strategy. This WHO operational handbook on tuberculosis. Module 6: tuberculosis and comorbidities aims to support countries in scaling up people-centred care,
...
Addressing comorbidities and risk factors for tuberculosis (TB) is a crucial component of the World Health Organization (WHO)’s End TB Strategy. This WHO operational handbook on tuberculosis. Module 6: tuberculosis and comorbidities aims to support countries in scaling up people-centred care, base
...
The guidelines are primarily intended for health-care professionals working in first- or second-level health-care facilities, including emergency, inpatient and outpatient services. They are also directed at policy-makers, health-care planners and programme managers, academic institutions, non-gover
...
In line with the Defeating meningitis by 2030: a global road map, the WHO guidelines on meningitis diagnosis, treatment and care Executive Summary provides a summary of the evidence-based recommendations for the clinical management of children and adults with community-acquired meningitis, including
...
Non-Communicable Diseases (NCDs) have emerged as conditions of great public health concern in Kenya accounting for 39% of deaths annually. The Ministry of Health through the Department of Non-Communicable Diseases has adopted the vision of achieving a nation free from preventable burden of NCDs. Fur
...
WHO guideline on HIV service delivery
recommended
Updated guidance on the integration of diabetes, hypertension and mental health services, and interventions to support adherence to antiretroviral therapy. The guideline offers practical implementation guidance for countries and key stakeholders as well as outlining key research gaps. As life expec
...
В сводном руководстве изложены меры общественного здравоохранения применительно к ВИЧ-инфекции, вирусным гепатитам и инфекциям, передаваемым половым путем (ИПП
...
Group psychological help for adults impaired by distress in communities exposed to adversity
With this manual, the World Health Organization (WHO) is responding to requests from colleagues around the world for a group version of the manual Problem Management Plus (PM+), which was developed for adul
...
Q6: In individuals with psychotic disorders (including schizophrenia) who require long term antipsychotic treatment, are anticholinergic medications more effective in preventing or reducing extrapyramidal side-effects and/or improving treatment adherence than placebo/treatment as usual?
Q 4: Is behavioural activation better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?brief, structured psychological treatment in non-specialist health care settings better (more effective than/as safe as) than treatment as usual in people with de
...
Q6: Is advice on physical activity better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder with inactive lifestyles
Q1: In individuals with psychotic disorders (including schizophrenia), are antipsychotic drugs safe and effective?
Q3: In individuals with a first psychotic episode with full remission, how long should antipsychotic drug treatment be continued after remission in order to allow for the best outcomes?
Q4: In individuals with long term and/or recurrent psychotic disorders (including schizophrenia), should individuals be maintained on pharmacotherapy indefinitely or withdrawn from treatment in order to allow for the best outcomes?
Q13: Are strategies aimed at improving community attitudes towards mental, neurological and substance use conditions (e.g. anti-stigma campaigns) feasible and effective?
